Italia markets open in 1 hour 27 minutes

Century Therapeutics, Inc. (IPSC)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
3,1400-0,5300 (-14,44%)
Alla chiusura: 04:00PM EDT
3,2500 +0,11 (+3,50%)
Dopo ore: 06:43PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente3,6700
Aperto3,9200
Denaro3,0700 x 100
Lettera3,1600 x 100
Min-Max giorno2,9850 - 3,6300
Intervallo di 52 settimane1,2800 - 5,5100
Volume308.918
Media Volume217.350
Capitalizzazione203,528M
Beta (5 anni mensile)1,34
Rapporto PE (ttm)N/D
EPS (ttm)-2,3000
Prossima data utiliN/D
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A14,83
  • GlobeNewswire

    Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference

    PHILADELPHIA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Greg Russotti, Ph.D., Interim Chief Executive Officer, will participate in a fireside chat at the Chardan 7th Annual Genetic Medicines Conference on Tuesday, October 3, 2023 at 9:00 AM ET. A replay of the event will be available on the “Events & Prese

  • GlobeNewswire

    Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

    – Company remains on track to report initial data from Schedule A of the ongoing Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas by year end – – Ended second quarter 2023 with cash, cash equivalents, and investments of $301.0 million; Cash runway expected into 2026 – PHILADELPHIA, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-d

  • GlobeNewswire

    Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

    – Preclinical data supporting selection of CNTY-101 as lead product candidate presented at AACR Annual Meeting – – Company remains on track to report initial data from Schedule A of the ongoing Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas by year end – – Ended first quarter 2023 with cash, cash equivalents, and investments of $334.8 million; Cash runway expected into 2026 – PHILADELPHIA, May 11, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASD